Connective tissue diseases and infections: Current debate;Maladies systémiques et infections: Questions actuelles

Presse Medicale

Volumn 25, Issue 8, 1996, Pages 370-378

  Lortholary, O ^a,b   Genereau T ^a   Jarrousse, B ^a   Guillevin, L ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; INFECTION; PROGNOSIS; REVIEW; RISK FACTOR; PNEUMOCYSTIS PNEUMONIA; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS;

CONNECTIVE TISSUE DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; PROGNOSIS; RISK FACTORS;

ANTIBIOTIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; NAFCILLIN; NORFLOXACIN; RIFAMPICIN;

EID: 34347274113     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Staples PJ, Gerding DN, Decker JL, Gordon RS Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974; 17:1-10
2. Généreau T, Lortholary O, Sauvaget F, Cohen P, Jarrousse B, Guillevin L Complications infectieuses des maladies systémiques. Med Mal Infect 1995; 25 976-84.
3. Kallenberg CG, Kimburg PC, Van Slochtheren C et al B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis Clin Exp Immunol 1983; 53:371-7
4. Alpert SD, Koide J, Takada S, Engleman EG. T cell regulatory disturbances in the rheumatic diseases. Rheum Dis Clin North Am 1987; 13:431-45.
5. Glaser C, Angulo F, Dueger E, Ford RB. Functional asplenia and pneumococcal sepsis in patients with systemic lupus erythematosus. Clin Infect Dis 1995; 20:194.
6. Généreau T, Cabane J. Bénéfice des corticoïdes lors du traitement de la maladie de Horton et de la pseudopolyarthrite rhizomélique avantages et inconvénients. Une méta-analyse. Rev Med Interne 1992; 13:387-91.
7. Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 1985; 55:271-87.
8. Soria LM, Nolla Sole JM, Sacanell AR, Garcia JV, Escofet DR. Infectious arthritis in patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51:402-3.
9. Kahn MF, Peltier AP, Podrabinek M, Tubiana M, de Seze S. Les infections dans le lupus érythémateux disséminé. Ann Med Interne 1977; 128:31-7.
10. Lehman TJ, Palmeri ST, Hastings C, Klippel JH, Plotz PH. Bacterial endocarditis complicating systemic lupus erythematosus. J Rheumatol 1983; 10:655-8.
11. Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1987; 17 126-41.
12. Suzuki A, Ohosone Y, Obana M et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994; 21:33-6.
13. Cacoub P, Du LT, Guillevin L, Godeau P. Les causes de mortalité au cours des vascularites systémiques du groupe de la périartérite noueuse. Ann Med Interne 1988; 139:381-90.
14. Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins lupus cohort. J Rheumatol 1992; 19:1559-65.
15. Watanabe Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991; 18:1180-4.
16. Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21:37-44.
17. Hellmann DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine 1987; 66:341-8.
18. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55:87-98.
19. e ed), Wallace DJ, Hannahs Hahn B eds Lea & Febiger, Philadelphia 1993:454-6
20. Guillevin L, Lhote F, Cohen P et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observations of 41 patients Medicine 1995; 74:238-53.
21. Marcellin P, Descamps V, Martinot-Peignous M et al. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection Gastroenterology 1993; 104:272-7.
22. Lupi-Herrera E, Sanchez-Torres G, Marcushamer G, Mispireta J, Horwitz S, Espino Vela J. Takayasu's arteritis. Clinical study of 107 cases Am Heart J 1977; 93:94-103.
23. Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drags. Clin Infect Dis 1995; 20:1010-36.
24. Généreau T, N'Guyen QT, Lortholary O, Cohen P, Guillevin L. Vasculantes d'origine virale Étiopathogénie et implications thérapeutiques. J Mal Vasc 1995; 20:1-7.
25. Weetman AP, Borysiewicz LK. Viruses and autoimmunity. Autoimmunity 1990; 5:277-92.
26. Chérin P, Herson S, Godeau P. Physiopathologie des dermatomyosites et polymyosites. Ann Med Interne 1990; 141:156-9.
27. Kennedy-Stoskopf SK, Zink MC, Jolly PE et al. Lentivirus-induced arthritis. Rheum Dis Clin North Am 1987; 13:235.
28. Maul GG, Jimenez SA, Riggs E, Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I sequence similarity with retroviral p30 gag protein suggests a possible cause for autoimmunity in systemic sclerosis Proc Natl Acad Sci USA 1989; 86:8492-6.
29. Ranki A, Kurki P, Riepponen S, Stephanson E. Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies Arthritis Rheum 1992; 35:1483-91.
30. Talal N, Dauphinée MJ, Dang H, Alexander SS, Hart DJ, Garry RF. Detection of serum antibodies to retroviral proteins in patients with primary Sjogren's syndrome (autoimmune exocrinopathy). Arthritis Rheum 1990; 33:774-81
31. Olsen RG, Tarr MJ, Mathes LE et al. Serological and virological evidence of human T-lymphotropic virus in systemic lupus erythematosus. Med Microbiol Immunol 1987; 176:53-64
32. Calabrese LH, Proffitt MR, Segal AM et al. Clinical significance of serologic reactivity to human T-cell lymphotropic virus type III (HTLV III) in patients with autoimmune disease Arthritis Rheum 1986; 29(suppl ):S21.
33. Talal N, Flescher E, Dang H. Are endogenous retroviruses involved in human autoimmune disease? J Autoimmunity 1992; 5(suppl. A):61-6.
34. Pinching AJ, Rees AJ, Pussel BA, Lockwood CM, Mitchison RS, Peters DK. Relapses in Wegener's granulomatosis: the role of infection. Br Med J 1980; 281:836-8
35. Cohen J. Infection in immunologically-mediated diseases: a review. J R Soc Med 1983; 76:508-13
36. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse in Wegener granulomatosis. Ann Intern Med 1994; 120:12-17.
37. Lee P, Urowitz MB, Bookman AA et al. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977; 46:1-32
38. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 1975; 58:243-64.
39. Guillevin L, Janot F, Beaufils H, Godeau P. Glomérulopathie proliférative au cours d'une septicémie à pneumocoques compliquant l'évolution d'une maladie lupique. Sem Hop Paris 1982; 58:1221-3.
40. Lohr KM, Barthelemy CR, Schwab JP, Haasler GB. Septic spondylodiscitis in ankylosing spondylitis. J Rheumatol 1987; 14:616-20.
41. Epstein JH, Zimmermann B, Ho G. Polyarticular septic arthritis. J Rheumatol 1986; 13:1105-7.
42. Benson CH, Hansdangkul V. Disseminated gonococcal infection in systemic lupus erythematosus. J Rheumatol 1983; 10:668-9.
43. Baethge BA, King JW, Husain F, Embree LJ. Case report: herpes zoster myelitis occurring during treament for systemic lupus erythematosus. Am J Med Sci 1989; 298:264-6.
44. Jones MM, Lidsky MD, Brewer EJ, Yow MD, Williamson WD. Congenital cytomegalovirus infection and maternal systemic lupus erythematosus: a case report. Arthritis Rheum 1986; 29:1402-4.
45. Hayes K, Symington G, Mackay IR Maternal immunosuppression and cytomegalovirus infection of the fetus. Aust NZ J Med 1979; 9:430-3.
46. Choy DS, Weiss A, Lin PT Progressive multifocal leukoencephalopathy following treatment for Wegener's granulomatosis. JAMA 1992; 268:600-1.
47. Tomura N, Watanabe M, Kato T, Nishino K, Kowada M. Case report: progressive multifocal leukoencephalopathy with prominent medullary veins on angiogram. Clin Radiol 1994; 49:66-8.
48. Iannarella G, Makdassi R, Schmit JL et al. Association d'une leucoencéphalite multifocale progressive et d'une sarcoïdose. Ann Med Interne 1992; 143:71-4.
49. Livneh A, Coman EA, Cho S, Lipstein-Kresch E. Strongyloides stercoralis hyperinfection mimicking systemic lupus erythematosus Arthritis Rheum 1988; 31:930-1.
50. Kalish RA, Knopf AN, Gary GW, Canoso JJ. Lupus-like presentation of human parvovirus B19 infection. J Rheumatol 1992; 19:169-71
51. Stahl NI, Klippel JH, Decker JL. Fever in systemic lupus erythematosus Am J Med 1979; 67:935-40.
52. Bradley JD, Brandt KD, Katz BP Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32:45-53.
53. Rubin RH, Ferraro MJ. Understanding and diagnosing infectious complications in the immmunocompromised host: current issues and trends Hematol/Oncol Clin North Am 1993; 7:795-812.
54. Weir AB, Herrod HG, Lester EP, Holbert J. Diffuse large-cell lymphoma of B-cell origin and deficient T-cell function in a patient with rheumatoid arthritis Arch Intern Med 1989; 149:1688-90.
55. Furie RA. Effects of human immunodeficiency virus infection on the expression of rheumatic illness Rheum Dis Clin North Am 1991; 17:177-88.
56. Guillevin L, Jarrousse B, Lok C et al Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparisons of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. J Rheumatol 1991; 18:567-74.
57. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids Rev Infect Dis 1989; 11:954-63
58. Clements PJ, Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum 1986; 15:231-54.
59. Dale DC, Petersdorf RG. Corticosteroids and infectious diseases Med Clin North Am 1973; 57:1277-87.
60. Ginsburg C, Guillevin L, Sauvaget F, Lhote F, Jarrousse B, Komarover H. Maladies systémiques traités par corticoïdes, échanges plasmatiques et cyclophosphamide: complications infectieuses et lymphopénie. Ann Med Interne 1993; 144:15-19.
61. Gënéreau T, Lortholary O, Leclerq P et al. Treatment of systemic vasculitis with cyclophosphamide and steroids daily oral low-dose cyclosphosphamide administration after failure of a pulse intravenous high-dose regiment in four patients. Br J Rheumatol 1994; 33:959-62.
62. Omdal R, Husby G, Koldingsnes W Intravenous and oral cyclophosphamide pulse therapy in rheumatic disease: side effects and complications. Clin Exp Rheumatol 1993; 11:283-8.
63. Nashel DJ. Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders. Med Clin North Am 1985; 69 817-40.
64. Martinez-Osuna P, Zwolinska JB, Sikes DA et al. Lack of immunosuppressive effect of low-dose oral methotrexate on lymphocytes in rheumatoid arthritis. Clin Exp Rheumatol 1993; 11:249-53.
65. Boerbooms AMTh, Kerstens PJSM, van Loenhout JWA, Mulder J, van de Putte LBA. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24:411-21.
66. Van der Veen MJ, Van der Heide A, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53:224-8.
67. Bridges SL, Lopez-Mendez A, Harn KH, Tracy IC, Alarcon GS. Should methotrexate be discontinued before elective orthopaedic surgery in patients with rheumatoid arthritis? J Rheumatol 1991; 18:984-8.
68. Cohen J, Pinching AJ, Rees AJ, Peters DK Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 1982; 51 I-15.
69. McCune WJ, Friedman AW. Immunosuppressive drug therapy for rheumatic diseases Curr Opin Rheumatol 1993; 5:282-92.
70. Faulds D, Goa KL, Benfield P. Cyclosporin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders Drugs 1993; 45:953-1040.
71. Roilides A, Pizzo PA Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts. In: Hematology/Oncology Clinics of North America, Infectious complications in the immunocompromised host I, Pizzo PA ed. 1993; 4:841-64.
72. Van der Straeten C, Wei N, Rotschild J, Goozh JL, Klippei JN. Rapidly fatal pneumococcal septicemia in systemic lupus erythematosus. J Rheumatol 1987; 14 1177-80.
73. Schwartz PE, Stenoff S, Mucha P, Melton LJ, Offord KP. Postsplenectomy sepsis and mortality in adults. JAMA 1982; 248:2279-83.
74. Guillevin L. Therapeutic plasma exchange: definite indications and rescue therapy rn rheumatic disease. Plasma Ther Transfus Technol 1985; 6:557-60.
75. Guillevin L, Lok C, Bussel A et al. Side effects during the treatment of polyarteritis nodosa and Churg-Strauss angiitis with corticosteroids, plasma exchange, and cyclophosphamide: 377 sessions in 30 patients. Plasma Ther Transfus Technol 1985; 6:557-60.
76. Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis JAMA 1980; 244:2423-6.
77. Jarrett MP, Santhanam S, DelGreco F. The clinical course of end-stage renal disease in systemic lupus erythematosus. Arch Intern Med 1983; 143:1353-6.
78. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampicin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med 1994; 154:1521-4.
79. Chosidow O, Herson S. Pharmacocinétique clinique des corticoides. Ann Med Interne 1994; 145(suppl 2):19-21.
80. Fauvelle F, Lortholary O, Tod M. Pharmocokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients. Antimicrob Agems Chemother 1994; 38:1519-22.
81. Billaud EM, Ropers J, Fortineau N, Kreft-Jais C, Babany G. Analyse critique des interactions médicamenteuses de la ciclosporine. Therapie 1992; 47:335-42.
82. Stansell JD, Hopewell PC. Pneumocystis carinii pneumonia: risk factors, clinical presentation and natural history. In: Bailliere's Clinical Infectious Diseases, Pneumocystis carinii, Slatter FR, Walzer PD eds. 1995; 2:449-59.
83. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocopromised adults. Med J Aust 1995; 162:233-5.
84. Ognibene FP, Shelhamer JH, Hoffman GS et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis Am J Respir Crit Care Med 1995; 151:795-9.
85. Jarrousse B, Guillevin L, Bindt P et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993; 11:615-21.
86. Godeau B, Coutant-Perronne V, Du LT et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 case J Rheumatol 1994; 21:246-51.
87. Huynh DU, Gantenbein H, Binswanger U. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic antoantibody-positive vasculitis. Arch Intern Med 1995; 155:872-4
88. Hughes WT Pneumocystis carinii infections in mothers, infants and non-AIDS elderly adults. In: Bailliere's Clinical Infectious Diseases, Pneumocystis carinii, Sattler FR, Walzer PD eds 1995; 2461-70.
89. Mounib B, Cabane J, Blum L, Picard O, Wattiaux MJ, Imbert JC. Le risque de pneumocystose nosocomiale chez les immunodéprimés non infectés par le virus de l'immunodéficience humaine. Rev Med Interne 1994; 15:95-100.
90. Bernstein CN, Kolodny M, Block E, Shanahan F. Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids Am J Gastroenterol 1993; 88:574-7.
91. Kovacs JA, Hiemenz JW, Macher AM et al. Pneumocystis carinii pneumonia a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100:663-71
92. Masur H. Algorithmic approach to treatment. In: Baillière's Clinical Infectious Diseases, Pneumocystis carinii, Sattler FR, Walzer PD eds. 1995; 2:531-49.
93. Skogberg K, Ruutu P, Tukiainen P, Valtonen V. Effect of immunosuppressive therapy on the clinical presentation and outcome of tuberculosis Clin Infect Dis 1993; 17:1012-17
94. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome A prospective study in 342 patients. Medicine 1996 (sous presse).
95. Girard PM, Bozzette SA. Strategies for prophylaxis of Pneumocystis carinii pneumonia In: Baillière's Clinical Infectious Diseases, Pneumocystis carinii, Slatter FR, Walzer PD eds 1995; 2:551-71.
96. Wakefield AE. Re-examination of epidemiological concepts. In: Baillière's Clinical Infectious Diseases. Pneumocystis carinii, Sattler FR, Walzer PD eds. 1995; 2:431-48.